Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: PI Accessory Mutations: None

PR Other Mutations: L10V xm - 112V xm - 113V xm - 616E xm - 835D xm - 835D xm - 857K xm - 163T xm - 164L xm - 169K xm - 189M x

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible Susceptible tipranavir/r (TPV/r)

PR comments

Other

L10(/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

RT Other Mutations: E6N ... V35T ... V50T ... V5

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC) Low-Level Resistance zidovudine (AZT) Susceptible stavudine (D4T) Susceptible

didanosine (DDI) Potential Low-Level Resistance
emtricitabine (FTC) High-Level Resistance
lamivudine (3TC) High-Level Resistance
tenofovir (TDF) Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

Susceptible

Intermediate Resistance

Potential Low-Level Resistance

High-Level Resistance

Low-Level Resistance

RT comments

NRTI

M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR.

Other

- . V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.
- . This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:						Download CSV		
Rule	ABC ÷	AZT ≑	D4T ≑	DDI ÷	FTC ÷	зтс ≑	TDF ÷	
M184MV	15	-10	-10	10	60	60	-10	

Drug resistance mutation scores of NNRT1:

Rule	DOR ‡	EFV ‡	ETR ≑	NVP ≑	RPV ≑
G190A	0	45	10	60	15


Download CSV -

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: T97TA - LONG A 2016

IN Other Mutations: E11D ... • K14R ... • V31I ... • S39H ... • K21R ... • V31I ... • K21R ... • V31I ... • K21R ... • K21R ... • K21R ... • K219N ...



HIVDB 9.5.1 (2023-11-0



RAL 0

10